Row No	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	14/SC/1161	155743	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients.	Number Agreed	50	50	Date Agreed	03/09/2018	116	03/05/2018	116	Recruitment Finished
2	17/SC/0242	222650	A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction	Number Agreed	4	4	Date Agreed	30/06/2018	2	29/06/2018	2	Recruitment Finished
3	18/YH/0167	246108	A Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered combination of GLPG3067, GLPG2222 and GLPG2737, in adult subjects with cystic fibr	Number Agreed	1	1	Date Agreed	31/12/2050	0	28/06/2018	0	Withdrawn By Sponsor
4	16/LO/0803	204170	Study of MiniMed? 640G Insulin Pump with SmartGuard? in prevention of Low Glucose Events in adults with Type 1diabetes	Range Agreed	5	7	Date Agreed	30/09/2017	6	03/04/2018	6	Recruitment Finished
5	16/EM/0436	213166	Single arm study of ALXN1210 in complement inhibitor treatment-naive adult and adolescent patients with atypical hemolytic uremic syndrome (aHUS)	Number Agreed	1	1	Date Agreed	28/02/2018	0	01/06/2018	0	Recruitment Finished
6	17/EE/0026	220207	A Prospective, Randomized, Controlled, Multi-Center Clinical Study of theACRYSOF IQ Extended Depth of Focus (EDF)	Number Agreed	12	12	Date Agreed	30/03/2018	9	06/04/2018	9	Recruitment Finished
7	17/LO/1502	232726	An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS443139 in Huntington?s Disease Patients Who Participated in Prior Investigational Studies of ISIS 443139	Range Agreed	1	4	Date Agreed	31/05/2019	4	24/04/2018	4	Recruitment Finished

Row No	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
8	17/LO/0794	223700	A 52-Week Multicenter, Randoimized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis who are Biologic Disease-Modifying Anti-Rheumatic Drug Naive	Number Agreed	2	2	Date Agreed	13/05/2019	1	18/05/2018	1	Recruitment Finished
9	16/LO/1211	207428	A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics,Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 versus EU sourced MabThera? in Anti TNFInadequate Responder Patients with Moderate to Seve	Range Agreed	1	2	Date Agreed	01/08/2018	0	20/07/2018	0	Recruitment Finished
10	18/NW/0412	247770	To evaluate the acceptability (including gastro intestinal tolerance and compliance) of a low calorie peptide based paediatric tube-feed formula for children over 1 year of age	Range Agreed	1	7	Date Agreed	31/08/2018	5	31/08/2018	5	Recruitment Finished
11	13/NW/0003	117310	AKPA 3-001: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Severe Sepsis and Coagulopathy	Range Agreed	1	6	Date Agreed	30/09/2018	3	13/09/2018	3	Recruitment Finished
12	13/NI/0123	135437	MILES - UK: Post marketing, multicenter, single arm, obervational clinical registry to evaluate safety and efficacy of BioMime sirolimus eluting stent system in all comers real world population with coronary artery stenosis in United Kingdom	Number Agreed	10	10	Date Agreed	31/07/2018	25	31/08/2018	25	Recruitment Finished
13	15/LO/1079	177212	A Phase 1/2 Study to Assess the Safety and Efficacy of MultiStem? Therapy in Subjects with Acute RespiratoryDistress Syndrome	Range Agreed	2	3	Date Agreed	31/03/2018	2	19/09/2018	4	Recruitment Finished
14	17/EE/0079	220827	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studyto Evaluate the Safety and Efficacy of CCX168 (Avacopan) inPatients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab orCyclophosph	Number Agreed	2	2	Date Agreed	31/12/2018	2	04/07/2018	2	Recruitment Finished

Row No	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
15	17/EM/0405	223871	A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis	Range Agreed	1	10	Date Agreed	30/09/2018	3	21/09/2018	3	Recruitment Finished
16	16/NW/0089	165834	IronWood	Number Agreed	40	40	Date Agreed	30/04/2017	18	01/08/2018	42	Recruitment Finished
17	17/LO/0683	226533	A Phase 2, Randomized, Double-blind, Controlled Study toEvaluate the Safety and Efficacy of VX-659 CombinationTherapy in Subjects Aged 18 Years and Older With CysticFibrosis	Number Agreed	4	4	Date Agreed	28/02/2018	1	02/04/2018	1	Recruitment Finished
18	18/NE/0103	241640	A Phase 3, randomized, double-blind, controlled study evaluating the efficacy and safety of VX-659 combination therapy in subjects with cystic fibrosis who are homozygous for the F508del Mutation (F/F)	Range Agreed	1	2	Date Agreed	31/01/2018	0	21/07/2018	2	Recruitment Finished
19	17/NW/0635	228844	A placebo-controlled, double-blind (sponsor open), randomised, crossover study to assess the efficacy, safety, and tolerability of GSK2798745 in participants with chronic cough	Number Agreed	10	10	Date Agreed	08/10/2018	0	28/09/2018	0	Withdrawn By Sponsor
20	18/NE/0104	241180	A phase 3, randomized, double-blind, controlled study evaluating the efficacy and safety of VX-659 combination therapyin subjects with cystic fibrosis who are heterozygous for the F508del mutation and a minimal function mutation (F/MF)	Number Agreed	2	2	Date Agreed	31/08/2018	0	21/07/2018	3	Recruitment Finished
21	18/LO/0068	235852	Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)	Number Agreed	1	1	Date Agreed	31/10/2019	0	10/10/2018	0	Withdrawn By Sponsor

Row No	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
22	18/NE/0200	244356	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)	Range Agreed	1	3	Date Agreed	31/10/2018	3	31/10/2018	3	Recruitment Finished
23	15/NW/0769	171345	CTP005 - A Feasibility study of the Use of ReCell? Autologous Cell Harvesting Device for Diabetic Foot Ulcers	Range Agreed	6	21	Date Agreed	31/12/2018	11	31/12/2018	11	Recruitment Finished
24	15/LO/2045	193136	A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation with SMT C1100 in Ambulatory Paediatric Male Subjects with Duchenne Muscular Dystrophy (C11005)	Range Agreed	1	2	Date Agreed	01/05/2018	2	27/06/2018	2	Recruitment Finished
25	15/NE/0167	171524	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	Number Agreed	2	2	Date Agreed	31/10/2018	2	08/10/2018	2	Recruitment Finished
26	17/NE/0115	218417	MULTICENTER, INTERNATIONAL, DOUBLE-BLIND, TWO-ARM, RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PIRFENIDONE IN PATIENTS WITH UNCLASSIFIABLE PROGRESSIVE FIBROSING ILD	Number Agreed	2	2	Date Agreed	30/04/2018	0	30/04/2018	0	Recruitment Finished
27	17/EE/0255	227279	VOLCANO 2	Number Agreed	10	10	Date Agreed	23/02/2018	0	11/04/2018	5	Recruitment Finished
28	17/YH/0313	232939	RelAxCough	Range Agreed	10	15	Date Agreed	30/11/2018	12	29/12/2018	12	Recruitment Finished

Row No	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
29	17/EM/0060	215678	Protocol I1F-MC-RHBY. A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in P	Number Agreed	2	2	Date Agreed	28/09/2018	2	28/09/2018	2	Recruitment Finished
30	17/EM/0324	225749	A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotidecapsules in patients who previously tolerated and demonstrated biochemical control on injectable somatostatinreceptor ligands (SRL	Range Agreed	1	2	Date Agreed	31/08/2018	2	01/10/2018	2	Recruitment Finished
31	18/SC/0098	241440	A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens	Number Agreed	2	2	Date Agreed	28/02/2019	2	30/08/2018	2	Recruitment Finished
32	16/EM/0193	190690	A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib oncardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): Thedal-GenE trial?.	Number Agreed	6	6	Date Agreed	01/11/2018	13	01/11/2018	13	Recruitment Finished
33	15/NW/0142	164099	Adapt Response	Number Agreed	20	20	Date Agreed	31/01/2019	10	31/01/2019	10	Recruitment Finished
34	15/WM/0453	172946	An Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 versus Fulvestrant in Postmenopausal Women with ER positive HER-2 negative Primary Breast Cancer	Number Agreed	1	1	Date Agreed		0	11/01/2019	26	Recruitment Finished
35	17/EM/0183	220783	A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasal polyps	Number Agreed	3	3	Date Agreed	22/06/2018	1	22/06/2018	1	Recruitment Finished

Row No	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
36	18/LO/0782	245936	A Randomized, Double Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Na?ve Participants with Neovascular Age-Related Macular Degeneration (AMD)	Range Agreed	1	4	Date Agreed	01/03/2019	1	01/03/2019	1	Recruitment Finished
37	18/EM/0228	248988	A double blind, placebo-controlled study to assess the anti-viral effect, safety and tolerability of inhaled PC786 for the treatment of acute respiratory syncytial virus (RSV) infection in adult hematopoietic stem cell transplant recipients	Number Agreed	3	3	Date Agreed	11/03/2019	1	12/03/2019	1	Recruitment Finished
38	16/LO/1012	205250	A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind,Placebo-controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy ofTolvaptan followed by a Two Year Open-label Extension in Children and AdolescentSubjects with Autoso	Range Agreed	1	5	Date Agreed	18/10/2020	9	15/11/2018	9	Recruitment Finished
39	16/NE/0255	200900	External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment with Raxone? in Leber?s Hereditary Optic Neuropathy (LHON)	Range Agreed	1	3	Date Agreed	28/02/2019	5	08/03/2019	7	Recruitment Finished
40	17/LO/0113	219400	A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally toPatients With Sickle Cell Disease	Range Agreed	1	6	Date Agreed	30/06/2018	2	19/03/2019	2	Recruitment Finished
41	17/SC/0237	220963	A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety,tolerability, pharmacodynamics, and pharmacokinetics of different doses of orally administered BI 1467335 during a12-week treatment period c	Number Agreed	4	4	Date Agreed	18/12/2018	1	07/02/2019	1	Recruitment Finished
42	17/EE/0204	207238	A randomized, double-blind, placebo-controlled, dose-ranging, study to evaluate the efficacy, safety and tolerability of single doses of BCX7353 as an acute attack treatment in subjects with hereditary angioedema	Range Agreed	1	2	Date Agreed	01/05/2018	0	01/05/2018	0	Recruitment Finished

Row No	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
43	16/LO/0878	201070	Prospective, multi-centre study to evaluate the everlinQ endoAVF System when used to create an endovascular arteriovenous fistula (endoAVF) for patients who require vascular access for haemodialysis.	Range Agreed	15	20	Date Agreed	31/12/2019	13	06/03/2019	13	Recruitment Finished